^
Association details:
| Biomarker: | PD-L2 expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
222-K Integrated immunoprofiling and RNA sequencing (RNA-seq) for anti-PD-1 response prediction in head and neck squamous cell carcinomas (HNSCC)
Published date:
11/04/2023
Excerpt:
We then stratified the 36 HNSCC patients treated with nivolumab into the same G1-G5 immunotypes as a validation cohort. At baseline, the G2 group had higher OR rates than other groups (p=0.02; figure 2). Baseline primary tumors showed OR correlated with PD-L1 and PD-L2 expression, interferon responsive genes, T-cell trafficking, and MHC class I pathway (higher values in Responders versus Non-responders, p<0.05; figure 3).
DOI:
10.1136/jitc-2023-SITC2023.0222-K
Trial ID:
